Novartis wins EU approval for Cosentyx in rheumatic disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| NOVARTIS AG (NYSE: NVS) | Delayed: 150.37 -5.9 (3.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.27 | 52 Week High | $89.15 | |||
| Open | $156.08 | 52 Week Low | $69.84 | |||
| Day High | $156.08 | P/E | N/A | |||
| Day Low | $149.67 | EPS | $0.00 | |||
| Volume | 1,335,868 | |||||
